Covid Vaccine Race

Reports of myocarditis were reported in mostly young adult males, 4 days after administration.

India pushes 300,000 COVID-19 death mark as worries of black fungus loom.

The company plans to file for Food and Drug Administration (FDA) authorization for the 12-17 year old population in early June.

The federal agency elongates the time from 5 days up to 1 month for thawed out doses of the Pfizer-BioNTech vaccine.

The European Union (EU) agrees to look at easing restrictions for travelers from outside the continent, depending on vaccine or country status.

A new CDC study demonstrates effectiveness in a population with high exposure to the virus.

The CDC Director Rochelle Walensky confirmed the Pfizer-BioNTech vaccine can be administered in children as young as 12 years of age.

Discriminately affected populations face a wall of hurdles, historic and contextual, in buying into COVID-19 vaccine benefit. What can clinicians and public health officials do to help?

The first US COVID-19 vaccine breaks ground again, as the first authorized for patients as young as 12 years old.

Malaysia begins nationwide lockdown due to third wave of the pandemic.

Investigators report the vaccine demonstrated it was safe, well-tolerated, and immunogenic in all age groups.

Novavax plans to deliver approximately 350 million doses to COVAX during the third quarter of 2021.

The vaccine will now be included in WHO’s COVAX initiative, which is providing greater and more equitable access to vaccines around the world.

Reaching a vaccination rate of 50% by July of 2021 could prevent 5.8 million cases and 215,790 hospitalizations.

The companies are seeking approval for anyone aged 16 and above.

Company plans to initiate a rolling submission for US Food and Drug Administration (FDA) Biologics License Application (BLA) this month for the vaccine.

Moderna reports data demonstrating a single 50 µg shot of its mRNA-1273 or mRNA-1273.351 booster shot increased neutralizing titers against SARS-CoV-2, as well as the South African and Brazilian variants.

New real-world research suggest the vaccine may help provide control of the pandemic virus.

Amongst HIV negative participants, the vaccine demonstrated a 51% efficaciousness against B.1.351.

The company will provide the vaccine group with 34 million doses in the fourth quarter of this year, and up to 466 million more doses in 2022.

A report said the vaccine may receive a US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the 12-15 year old population as early as next week.

Antibody levels induced by mRNA COVID-19 vaccines are much higher than those induced by natural infection and confer cross-reactivity that could be effective against new variants, a new study from the University of California, Irvine, found.

A treatment arm of up to 3000 participants aged 12-17 years old will be rolled into the North American-based PREVENT-19 trial.

The report details what symptoms vaccinated people should look out for, as well as treatment details for healthcare professionals.

With its mRNA COVID-19 vaccine authorized, the company is employing the technology to take aim at a variety of pathogens.

A pair of recent studies suggest that the ability of people with blood cancers lymphocytic leukemia and multiple myeloma to produce antibodies in response to COVID-19 vaccines is impaired.

Surveys suggest most students plan to get the shots anyway.

The Biden Administration plans to donate the AstraZeneca vaccines globally upon clearance of safety reviews.

Thailand steps up travel restrictions among a rapidly spreading third wave of the disease.

Nursing home residents who had recovered from COVID-19 showed robust antibody levels against the SARS-CoV-2 spike protein after 1 dose of messenger RNA (mRNA) vaccine, a study in France showed.